ATE506957T1 - Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen - Google Patents

Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen

Info

Publication number
ATE506957T1
ATE506957T1 AT07742308T AT07742308T ATE506957T1 AT E506957 T1 ATE506957 T1 AT E506957T1 AT 07742308 T AT07742308 T AT 07742308T AT 07742308 T AT07742308 T AT 07742308T AT E506957 T1 ATE506957 T1 AT E506957T1
Authority
AT
Austria
Prior art keywords
protein
prophylactic
therapeutic agent
neurodegenerative diseases
acid sequence
Prior art date
Application number
AT07742308T
Other languages
English (en)
Inventor
Hitoshi Okazawa
Original Assignee
Nat Univ Corp Tokyo Med & Dent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Corp Tokyo Med & Dent filed Critical Nat Univ Corp Tokyo Med & Dent
Application granted granted Critical
Publication of ATE506957T1 publication Critical patent/ATE506957T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AT07742308T 2006-06-01 2007-04-24 Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen ATE506957T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006154059A JP4982739B2 (ja) 2006-06-01 2006-06-01 ポリグルタミン病の予防・治療剤
PCT/JP2007/058873 WO2007138810A1 (ja) 2006-06-01 2007-04-24 神経変性疾患の予防・治療剤

Publications (1)

Publication Number Publication Date
ATE506957T1 true ATE506957T1 (de) 2011-05-15

Family

ID=38778331

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07742308T ATE506957T1 (de) 2006-06-01 2007-04-24 Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen

Country Status (6)

Country Link
US (1) US7833975B2 (de)
EP (1) EP2039367B1 (de)
JP (1) JP4982739B2 (de)
AT (1) ATE506957T1 (de)
DE (1) DE602007014210D1 (de)
WO (1) WO2007138810A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
CN104825491A (zh) 2009-10-28 2015-08-12 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
CN114106139A (zh) 2011-04-26 2022-03-01 斯特姆里姆有限公司 用于诱导组织再生的肽及其应用
PL2913058T3 (pl) 2012-10-25 2018-04-30 Genomix Co., Ltd. Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1
MX365899B (es) * 2012-10-25 2019-06-19 Univ Osaka Composición farmacéutica que comprende un fragmento de péptido de hmgb1 para usarse en tratamiento de daño a la medula espinal.
WO2015053402A1 (ja) * 2013-10-11 2015-04-16 国立大学法人東京医科歯科大学 脊髄小脳変性症を予防又は治療するための薬剤
EP3502248A4 (de) 2016-08-09 2020-04-22 National University Corporation Tokyo Medical and Dental University Antikörper gegen hmgb1 und zusammensetzung damit zur behandlung oder vorbeugung von morbus alzheimer
JP6984815B2 (ja) * 2016-09-12 2021-12-22 国立大学法人 東京医科歯科大学 神経変性疾患タンパク質の異常凝集を伴って発症する神経疾患に対する予防又は治療剤、及び上記予防又は治療剤のスクリーニング方法
EP3718561A4 (de) 2017-12-01 2021-07-21 Stemrim Inc. Therapeutikum für entzündliche darmerkrankung
WO2021242180A1 (en) * 2020-04-22 2021-12-02 Chulalongkorn University A composition and a method of rejuvenating dna and preventing dna damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4255101B2 (ja) 2002-03-15 2009-04-15 独立行政法人理化学研究所 神経変性疾患の治療薬
AU2004203732A1 (en) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of HMGB, HMGN, HMGA proteins
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
US7288250B2 (en) * 2003-09-11 2007-10-30 Critical Therapeutics, Inc. Monoclonal antibodies against HMGB1
US7618793B2 (en) * 2004-10-20 2009-11-17 The Regents Of The University Of Washington Identifying agents for decreasing cellular toxicity associated with huntingin polypeptide

Also Published As

Publication number Publication date
EP2039367A4 (de) 2009-12-30
JP2007320919A (ja) 2007-12-13
JP4982739B2 (ja) 2012-07-25
US7833975B2 (en) 2010-11-16
WO2007138810A1 (ja) 2007-12-06
US20090280488A1 (en) 2009-11-12
DE602007014210D1 (de) 2011-06-09
EP2039367B1 (de) 2011-04-27
EP2039367A1 (de) 2009-03-25

Similar Documents

Publication Publication Date Title
ATE506957T1 (de) Prophylaktisches/therapeutisches mittel für neurodegenerative erkrankungen
ATE483027T1 (de) Rekombinante n-glykosylierte proteine aus prokaryontischen zellen
MX2008009493A (es) Peptido novedoso y uso del mismo.
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
TNSN08064A1 (en) Albumin fusion proteins
HK1134283A1 (en) Arylsulfonamide compounds
SG170116A1 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP2455462A3 (de) Lipasevarianten zur pharmazeutischen Verwendung
ATE417595T1 (de) Keratin-bindende polypeptide
NO20054769L (no) Substituerte fenylalkansyrer
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
IN2012DN03368A (de)
MX2009006617A (es) Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales.
WO2011036443A9 (en) S1 protease c- terminal polypeptides and uses thereof for treating inflammation or coagulation disorders
WO2007132292A3 (en) Therapy for alzheimer's disease
WO2008051326A3 (en) Identification of contactins and l1- cams as ligands for the amyloid precursor protein
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
HK1121383A1 (en) Wound healing agent and composition
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
HK1145397A1 (en) Peptides derived from plasminogen activator inhibitor-1 and uses thereof
WO2007002739A3 (en) Chromium-amino acid complexes in the treatment of diabetes and other diseases
WO2007049065A3 (en) Vwfa, collagen and kunitz domain containing protein
WO2009010957A3 (en) Heparanase c-terminal domain, sequences derived therefrom, substances directed against said domain and uses thereof as modulators of heparanase biological activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties